Jon Cohen, John TravisScience’s COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation.A third COVID-19 vaccine candidate has convincing evidence that it works, and it may be easier to distribute and cheaper than the two other vaccines already shown to protect people.
Developed by the company AstraZeneca in partnership with the University of Oxford, the vaccine had an average efficacy of 70% in preventing the disease, the developers announce today in press releases.
In one dosing scheme, its efficacy was 90%, according to results from the interim analysis of clinical trial data.AstraZeneca says about 3 billion doses of the vaccine could be ready in 2021.